Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Kochanek

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Gene Therapy|October 16, 2004
Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in uteroR Bilbao, D P Reay, E Wu, et al.
Human Gene Therapy|February 27, 1999
DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscleH H Chen, L M Mack, S Y Choi, et al.
Gene Therapy|January 16, 2004
Foamy virus--adenovirus hybrid vectorsM Picard-Maureau, F Kreppel, D Lindemann, et al.
Experimental Neurology|May 18, 2004
Iris pigment epithelial cells: a possible cell source for the future treatment of neurodegenerative diseasesS Arnhold, I Semkova, C Andressen, et al.
Gene Therapy|November 1, 1996
In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genesP R Clemens, S Kochanek, Y Sunada, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 16, 2001
Local high-capacity adenovirus-mediated mCTLA4Ig and mCD40Ig expression prolongs recombinant gene expression in skeletal muscleZ L Jiang, D Reay, F Kreppel, et al.
Cell Transplantation|January 10, 2003
Intracerebral transplantation and successful integration of astrocytes following genetic modification with a high-capacity adenoviral vectorS Arnhold, F Kreppel, S Kandirali, et al.
Gene Therapy|September 10, 2003
Fetal muscle gene transfer is not enhanced by an RGD capsid modification to high-capacity adenoviral vectorsR Bilbao, D P Reay, T Hughes, et al.
Molecular Medicine (Cambridge, Mass.)|August 31, 2000
Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vectorW K O'Neal, H Zhou, N Morral, et al.
Gene Therapy|March 12, 2010
An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human bloodA Danielsson, G Elgue, B M Nilsson, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Gene Therapy|October 16, 2004
Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in uteroR Bilbao, D P Reay, E Wu, et al.
Human Gene Therapy|February 27, 1999
DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscleH H Chen, L M Mack, S Y Choi, et al.
Gene Therapy|January 16, 2004
Foamy virus--adenovirus hybrid vectorsM Picard-Maureau, F Kreppel, D Lindemann, et al.
Experimental Neurology|May 18, 2004
Iris pigment epithelial cells: a possible cell source for the future treatment of neurodegenerative diseasesS Arnhold, I Semkova, C Andressen, et al.
Gene Therapy|November 1, 1996
In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genesP R Clemens, S Kochanek, Y Sunada, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 16, 2001
Local high-capacity adenovirus-mediated mCTLA4Ig and mCD40Ig expression prolongs recombinant gene expression in skeletal muscleZ L Jiang, D Reay, F Kreppel, et al.
Cell Transplantation|January 10, 2003
Intracerebral transplantation and successful integration of astrocytes following genetic modification with a high-capacity adenoviral vectorS Arnhold, F Kreppel, S Kandirali, et al.
Gene Therapy|September 10, 2003
Fetal muscle gene transfer is not enhanced by an RGD capsid modification to high-capacity adenoviral vectorsR Bilbao, D P Reay, T Hughes, et al.
Molecular Medicine (Cambridge, Mass.)|August 31, 2000
Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vectorW K O'Neal, H Zhou, N Morral, et al.
Gene Therapy|March 12, 2010
An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human bloodA Danielsson, G Elgue, B M Nilsson, et al.
Pageof 6